Palifermin: The Only FDA-Approved Compound in This Cluster — and What That Actually Means for Everyone Else

Palifermin is the odd member of Cluster B. It is the only compound here with FDA approval — the only one backed by a Phase III randomized controlled trial published in the New England Journal of Medicine. It is also a compound that almost no Peptidings reader will ever use. The approval is narrow, the price is high, and the drug is not available outside hospital oncology settings.

But palifermin earns its place in this cluster for a different reason. It is a reference point. When we evaluate BPC-157’s wound healing evidence or KPV’s gut inflammation data, the question is always “how strong is this evidence, really?” Palifermin shows what the answer looks like when it is strong. A 212-patient double-blind RCT. A 35-percentage-point reduction in severe mucositis. FDA review, approval, and post-marketing surveillance. That is the bar. Understanding it helps you judge everything else in this cluster honestly.

Palifermin is a lab-made copy of keratinocyte growth factor, or KGF — a 164-amino-acid protein your body produces naturally. KGF (also called FGF-7) is made by fibroblasts and acts exclusively on epithelial cells — the cells lining your mouth, gut, lungs, and skin. It tells those cells to grow, divide, and survive damage. In cancer patients receiving bone marrow transplants, the chemotherapy and radiation destroy the lining of the mouth. The resulting ulcers are so severe that patients cannot eat, speak, or swallow. Palifermin rebuilds that lining. That is what it is proven to do. This article explains the science, the clinical data, and what palifermin’s existence means for the rest of the compounds in this cluster.

Quick Facts: KGF / Palifermin at a Glance

What Is KGF / Palifermin?

Keratinocyte growth factor (KGF) is a naturally occurring protein in the fibroblast growth factor (FGF) family — specifically, it is FGF-7. It was identified as a distinct growth factor in the late 1980s and characterized as a paracrine mediator: fibroblasts (mesenchymal cells) produce it, and epithelial cells respond to it. This directional specificity is a defining feature of KGF biology — it acts only on cells that express the FGFR2b receptor, which is the epithelial-specific splice variant of fibroblast growth factor receptor 2.

Palifermin is the pharmaceutical version — recombinant human KGF (rhKGF) produced in E. coli bacterial expression systems. It is a truncated version of the native protein: 164 amino acids of the mature KGF sequence, minus the signal peptide. At ~18,900 daltons, it is by far the largest molecule in Cluster B. To put this in context: BPC-157 is 15 amino acids. KPV is 3 amino acids. Thymosin Beta-4 is 43 amino acids. Palifermin is 164 amino acids — a full protein that cannot be manufactured by the solid-phase peptide synthesis methods used to make the other compounds in this cluster. It requires recombinant DNA technology, cell culture, purification, and quality control processes identical to those used for monoclonal antibodies and other biological drugs.

This manufacturing reality is not just a technical footnote. It is the reason palifermin costs $11,000+ per treatment course instead of $50 per vial. It is the reason no compounding pharmacy or research supplier sells it. And it is the reason that palifermin, despite being the most strongly evidenced compound in this cluster, is essentially invisible in the biohacking world.

The Gold Standard — What FDA Approval Actually Looks Like

Every compound in Cluster B is evaluated against a question that readers carry whether they articulate it or not: “Is the evidence good enough?” Palifermin is the article that shows what “good enough for FDA approval” actually requires.

The Spielberger Trial (2004)

Spielberger R, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med. 2004;351(25):2590–2598. PMID: 15602019.

Study design: double-blind, placebo-controlled, randomized trial. 212 patients with hematologic malignancies (lymphoma, leukemia, myeloma). All patients received identical myeloablative conditioning: fractionated total-body irradiation + high-dose chemotherapy + autologous hematopoietic stem cell transplantation. Randomized 1:1 to palifermin (60 μg/kg/day IV × 3 days pre-conditioning + 3 days post-transplant) or placebo. Primary endpoint: incidence of WHO Grade 3–4 oral mucositis over 28 days. Assessed by trained evaluators using a validated WHO mucositis grading scale.

Results: WHO Grade 3–4 mucositis: 63% (palifermin) vs. 98% (placebo) — p<0.001. WHO Grade 4 (most severe): 20% vs. 62% — a threefold reduction. Median duration of Grade 3–4 mucositis: 6 days vs. 9 days. Reduced patient-reported mouth soreness (validated scale). Reduced opioid analgesic use. Parenteral nutrition: 31% vs. 55% — patients could eat sooner. No increase in infection, relapse, or mortality.

This is what Phase III evidence looks like: a specific population, a defined intervention, blinded evaluation, a clinically meaningful primary endpoint, and a result large enough to change practice. When we say BPC-157 has “no controlled human trials” or KPV is “preclinical only,” this is the standard they are being measured against.

What It Took to Get Here

Before the Spielberger trial, palifermin went through: discovery and characterization of KGF biology, recombinant protein development and manufacturing, preclinical safety and efficacy studies in animal models, Phase I dose-finding studies in humans, Phase II proof-of-concept trials, Phase III pivotal trial, FDA review of the complete data package, manufacturing facility inspection and approval, and post-marketing surveillance commitments. This process took over a decade and hundreds of millions of dollars. Every other compound in Cluster B sits somewhere in the early stages of this pipeline. None has completed a Phase III trial for any indication.

Mechanism of Action

FGFR2b Specificity — The Epithelial Lock-and-Key

KGF binds exclusively to FGFR2b — a receptor found only on epithelial cells. This specificity is important because it means KGF does not activate fibroblasts, endothelial cells, neurons, or muscle cells. It is an epithelial-specific growth signal.

FGFR2b is the “IIIb” splice variant of fibroblast growth factor receptor 2. The alternative splice variant, FGFR2c (the “IIIc” isoform), is expressed on mesenchymal cells and responds to different FGF ligands. This splice-variant specificity is a natural safeguard: the paracrine loop runs in one direction only — mesenchymal cells produce KGF, epithelial cells receive the signal. Binding requires heparan sulfate proteoglycans as obligatory co-receptors. KGF + heparan sulfate together cause FGFR2b dimerization, activating the intracellular kinase domain.

Downstream Signaling

FGFR2b activation triggers: (1) RAS/MAPK pathway (predominant) — drives cell proliferation; (2) PI3K/AKT pathway — promotes cell survival, inhibits apoptosis; (3) PLCγ pathway — calcium signaling, cell differentiation; (4) PAK4 pathway — cell migration and morphogenesis.

What This Means for Mucosal Protection

In the context of stem cell transplantation: myeloablative chemotherapy and radiation destroy rapidly dividing cells — including the mucosal epithelial cells lining the mouth and GI tract. Palifermin administered pre-conditioning stimulates epithelial cell proliferation, building up a thicker mucosal barrier before the damage hits. It also activates cytoprotective pathways (PI3K/AKT) that help surviving epithelial cells resist chemotherapy-induced apoptosis. Post-transplant doses accelerate epithelial regeneration during the recovery phase. The result: less mucosal breakdown, fewer ulcers, less pain, less opioid use, less need for IV nutrition, and faster recovery of the ability to eat and swallow.

Clinical Evidence — Beyond the Approved Indication

GI Mucositis (Exploratory)

Lucchese A et al. (2014). PMID: 25142189. Randomized trial in AML patients (n=155). Palifermin vs. placebo during induction chemotherapy. Grade 3–4 GI adverse events: 21% (palifermin) vs. 44% (placebo), p=0.003. Severe diarrhea: 8% vs. 26%, p=0.01. This is the strongest evidence for palifermin outside its approved indication, but it remains a single exploratory trial — NOT the basis for FDA approval.

Graft-Versus-Host Disease (GVHD)

Mouse models show KGF protects intestinal epithelium and may prevent GVHD development. Clinical translation has been limited. Meta-analysis of 6 HSCT RCTs showed mixed results on acute GVHD outcomes (PMID: 29416437). Palifermin is NOT indicated or proven effective for GVHD prevention.

Solid Tumor Mucositis (Off-Label)

Meta-analysis of 10 RCTs across solid and hematologic malignancies: up to 24% relative reduction in severe mucositis in solid tumors (vs. 37% in hematologic malignancies). However, the FDA label explicitly states efficacy has not been established in patients with non-hematologic malignancies, and the label warns against use near solid tumors.

Wound Healing (Preclinical Only)

Mouse models: KGF-1 promoted 92% wound closure at day 12 vs. 40% control. 85% more new blood vessels in treated wounds. Enhanced epithelialization. Promising but entirely animal data — zero human wound healing trials exist.

Thymic Regeneration (Preclinical)

KGF induces transient expansion of thymic epithelial cells, promoting T-cell development. Returns to baseline within 2 weeks. Theoretical relevance for immune reconstitution after stem cell transplant. No clinical application yet.

IBD (No Data)

No published clinical trial of palifermin for inflammatory bowel disease. Given FGFR2b expression in GI epithelium, theoretical rationale exists, but no one has tested it.

The Cancer Question

KGF promotes epithelial cell proliferation. Many cancers arise from epithelial cells. Does giving more KGF promote cancer?

The Theoretical Concern

FGFR2b is expressed by many epithelial tumors. KGF binding could theoretically stimulate tumor cell growth, inhibit apoptosis, or protect tumor cells from chemotherapy — the same mechanisms that protect healthy epithelial cells.

What the Data Shows

In vitro: Conflicting results. Some FGFR2b-expressing tumor cell lines respond to KGF. Others show growth inhibition when FGFR2b is restored. The picture is not simple.

Animal models: Some evidence of tumor growth stimulation in non-hematopoietic tumor models.

Clinical trials: NO evidence of increased cancer incidence, relapse, or tumor progression in patients receiving palifermin in the pivotal trial or subsequent studies. Long-term follow-up is ongoing.

The FDA’s Position

The Kepivance label includes a precautionary warning: evidence of “tumor growth and stimulation in cell culture and in animal models of non-hematopoietic human tumors.” This is a warning, not a black box. There is no contraindication for hematologic malignancy patients. The label explicitly states efficacy and safety have not been established in solid tumor patients.

The Timing Rule

Palifermin must NOT be given within 24 hours before, during, or within 24 hours after chemotherapy. In trials where palifermin was given within this window, mucositis severity and duration increased. The drug protects epithelial cells from chemotherapy damage — but if given too close to chemo, it may protect tumor cells too.

Safety and Side Effect Profile

Known Adverse Effects (from Clinical Trials)

Skin reactions (most common): Rash (up to 62% incidence), pruritus/itching (up to 35%), erythema (up to 32%), edema. Median onset: 6 days after first dose; median duration: 5 days. Grade 3 skin rash: ~3% (comparable to placebo at ~2%).

Oral/perioral effects: Dysesthesia (abnormal sensation) around the mouth (~12%), tongue thickening and discoloration, taste alteration.

Systemic effects: Arthralgias (joint pain), mild non-specific pain. Generally mild-to-moderate and self-limiting.

Serious adverse events: Grade 3 skin rash occurred in <1% of patients. No serious life-threatening toxicities documented in trials. No increase in infection, graft failure, or mortality.

Overall Safety Profile

Palifermin’s side effects are predictable extensions of its mechanism — it promotes epithelial growth, so skin and mucosal symptoms (rash, tongue changes, perioral tingling) predominate. The safety profile is well-characterized from clinical trial data with 400+ patients and is generally considered favorable relative to the severity of the condition it treats (Grade 3–4 mucositis causes severe pain, inability to eat, and opioid dependence).

Anti-Doping Status

KGF/palifermin is not listed on the WADA Prohibited List. It is not a growth hormone, anabolic agent, or erythropoietin-related substance. As a recombinant protein used exclusively in oncology supportive care and available only by IV prescription, it has no relevance to athletic performance enhancement.

Legal and Regulatory Status

United States: FDA-approved (December 15, 2004). Prescription required. Available only through hospital pharmacies and specialty distributors as branded Kepivance.

No generic or biosimilar currently available. Palifermin is a biologic (recombinant protein), eligible for biosimilar competition under the BPCIA pathway. Updated FDA biosimilar guidance (March 2026) may streamline future development, but no biosimilar programs are publicly disclosed.

Not available from compounding pharmacies. The 164-amino-acid recombinant protein cannot be synthesized by compounding pharmacies and is not on any FDA compounding bulk drug substance list.

Not available from research chemical suppliers in pharmaceutical-grade formulation for human use.

Dosing — The Clinical Regimen

FDA-Approved Dosing

Route: Intravenous (IV) bolus injection. Dose: 60 μg/kg/day. Schedule: 3 consecutive daily doses before myeloablative conditioning (third dose 24–48 hours before therapy) + 3 consecutive daily doses after stem cell infusion. Total: 6 doses per treatment course.

Critical timing restriction: Palifermin must NOT be administered within 24 hours before, during, or within 24 hours after myelotoxic chemotherapy. Administration within this window increased mucositis severity and duration in clinical trials.

Preparation and Storage

Form: Lyophilized powder for reconstitution (6.25 mg per single-use vial). Reconstitution: 1.2 mL Sterile Water for Injection, USP. Concentration after reconstitution: 5 mg/mL.

Storage (unreconstituted): 2–8°C (36–46°F). Protect from light. Do not freeze.

Storage (reconstituted): Room temperature for up to 1 hour. Refrigerated for up to 24 hours. Do NOT freeze reconstituted solution. Discard any unused portion.

Administration: IV bolus injection. Do not use in-line filters. Do not dilute with saline (heparin-containing solutions cause precipitation).

Related Compounds

FGF-10 (KGF-2): A close relative in the FGF family that also signals through FGFR2b. Sometimes called KGF-2. Similar biological activity to KGF-1 but less clinically developed. No FDA-approved product.

FGF-2 (bFGF): Basic fibroblast growth factor. A broader-acting FGF that promotes wound healing through angiogenesis and fibroblast proliferation. Different receptor specificity (FGFR1, FGFR2c). Used in research wound healing models, sometimes in combination with KGF.

BPC-157: Shares wound healing overlap but through entirely different mechanisms (VEGF pathway, growth factor modulation vs. FGFR2b epithelial proliferation). BPC-157 is a 15-amino-acid synthetic peptide; palifermin is a 164-amino-acid recombinant protein. BPC-157 has no controlled human trials; palifermin has Phase III data. See BPC-157 article.

GHK-Cu: Wound healing peptide acting through copper-dependent enzyme activation. Different mechanism from KGF. 3 amino acids vs. 164 amino acids. See GHK-Cu article.

Cluster B Comparison Table

Compound	Type	Primary Target	Half-Life	FDA Status	WADA Status	Evidence Tier	Primary Tissue Target	Route	Human Evidence Status	Key Differentiator
BPC-157	Synthetic pentadecapeptide (15 amino acids, derived from gastric protective protein BPC)	VEGF / Nitric oxide (proposed multi-target)	~2–6 hours	Not FDA-approved	Prohibited — S0 (Non-Approved Substances)	Tier 3 — Pilot / Limited Human Data	Musculoskeletal, tendon, ligament, GI tract, CNS	Subcutaneous injection + Oral (both routes studied)	3 published human pilot studies (~30 subjects combined); no RCTs	Broadest tissue tropism in cluster. Only injury-repair peptide with both oral and injectable evidence. Most evidence in rodent models
TB-500	Synthetic 4-amino-acid fragment (residues 17–23 of Thymosin Beta-4)	Actin binding (cell migration, angiogenesis)	~2–3 hours	Not FDA-approved	Prohibited — S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics)	Tier 4 — Preclinical Only	Musculoskeletal (muscle, tendon, ligament), cardiac, neurological	Subcutaneous injection	Zero published human clinical trials; animal models and cell culture only	Smallest fragment studied; synthetic derivative of endogenous Thymosin Beta-4. Actin sequestration may drive cell migration
Thymosin Beta-4	Endogenous 43-amino-acid peptide (ubiquitous actin-sequestering protein)	Actin binding, cell migration, angiogenesis	~2–4 hours	Not FDA-approved	Prohibited — S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics)	Tier 3 — Pilot / Limited Human Data	Broad: muscle, cardiac, neurological, immune, epithelial	Subcutaneous injection + Topical (cosmetics)	Few human studies; cardiac regeneration in early-stage human data; cosmetic formulations	Full-length parent peptide of TB-500. Endogenous compound; ubiquitous in mammalian tissues. More potent than TB-500 fragment in vitro
GHK-Cu	Synthetic tripeptide-copper complex (Gly-His-Lys chelated to Cu2+)	Collagen synthesis, wound healing, TGF-beta modulation	~2 hours topical; ~4–6 hours systemic (estimated)	Not FDA-approved (topical in cosmetics; injectable investigational)	Prohibited — S0 (injectable as growth factor analog); topical unregulated	Tier 5 — It's Complicated	Dermal (collagen, elastin remodeling); broad systemic effects proposed but unverified	Topical (cosmetics — extensive evidence) vs. Subcutaneous injection (preclinical only)	Topical: 30+ years cosmetic use data; Injectable: zero human trials	Route-dependent evidence: topical skin rejuvenation well-established, but injectable claims extrapolate from fundamentally different delivery
AHK-Cu	Synthetic copper tripeptide variant (Ala-His-Lys chelated to Cu2+)	Copper chelation, extracellular matrix remodeling, growth factor signaling	~2–4 hours (estimated)	Not FDA-approved	Not WADA-listed	Tier 4 — Preclinical Only	Dermal (hair follicle, scalp), cosmetic	Topical (cosmetics)	No human clinical trials; in vitro and cosmetic formulation data only	GHK-Cu structural analog with alanine substitution. Primarily studied for hair growth. Less evidence base than GHK-Cu
LL-37	Human cathelicidin antimicrobial peptide (37 amino acids)	Antimicrobial, wound healing, angiogenesis, vitamin D-regulated immune modulation	~2–4 hours	Not FDA-approved	Not WADA-listed	Tier 3 — Pilot / Limited Human Data	Skin, mucosal surfaces, immune system	Subcutaneous injection, Topical	Limited human data; antimicrobial efficacy well-characterized in vitro; wound healing in animal models	Endogenous host defense peptide. Dual role: direct antimicrobial activity + immune modulation. Vitamin D pathway regulates expression
KPV	Alpha-MSH C-terminal tripeptide (Lys-Pro-Val)	NF-kB inhibition, anti-inflammatory (no melanocortin receptor activation)	~1–2 hours (estimated)	Not FDA-approved	Not WADA-listed	Tier 4 — Preclinical Only	GI tract (colitis models), skin, immune system	Subcutaneous injection, Oral (investigational)	No published human clinical trials; animal models (colitis, dermatitis) only	Smallest anti-inflammatory peptide in cluster (3 amino acids). NF-kB pathway without melanocortin receptor binding. GI-focused research
VIP	Endogenous 28-amino-acid neuropeptide (vasoactive intestinal peptide)	VPAC1/VPAC2 receptor agonism; vasodilation, immunomodulation, bronchodilation	~1–2 minutes (extremely short)	Not FDA-approved (aviptadil in clinical trials)	Not WADA-listed	Tier 2 — Clinical Trials	Pulmonary, GI tract, immune system, neurological	Subcutaneous injection, IV infusion, Intranasal	Multiple Phase 2 trials (ARDS, pulmonary hypertension, sarcoidosis); aviptadil in FDA pipeline	Shortest half-life in cluster. CIRS protocol use. Aviptadil (synthetic VIP) is furthest along FDA pathway among non-approved compounds here
KGF / Palifermin	Recombinant keratinocyte growth factor (FGF-7)	FGFR2b receptor; keratinocyte proliferation, epithelial barrier repair	~3–5 hours	FDA-approved (Kepivance for oral mucositis)	Not WADA-listed	Tier 1 — Approved Drug	Epithelial surfaces (oral mucosa, GI tract, skin)	Intravenous injection (FDA-approved route)	FDA-approved for chemo-induced oral mucositis; multiple Phase 2/3 trials	Only FDA-approved compound in Cluster B. Specific to epithelial tissues. IV-only approved route limits off-label accessibility
Substance P	Endogenous 11-amino-acid tachykinin neuropeptide	NK1 receptor agonism; fibroblast migration, angiogenesis, immune activation	~1–2 minutes	Not FDA-approved	Not WADA-listed	Tier 3 — Pilot / Limited Human Data	Corneal epithelium, skin, nervous system	Topical (corneal), Subcutaneous injection	Human data primarily in corneal wound healing; limited systemic human studies	Endogenous pain signaling peptide repurposed for tissue repair. Strongest human evidence in corneal healing. Dual role: nociception + repair
PRP	Autologous platelet-rich plasma (concentrated growth factor preparation)	PDGF, VEGF, TGF-beta release via platelet degranulation	N/A (not a single molecule)	FDA-cleared devices (not drug-approved)	Prohibited — M1 (Manipulation of Blood and Blood Components)	Tier 2 — Clinical Trials	Musculoskeletal (tendon, cartilage, bone), dermal, hair	Injection (local to injury site)	Hundreds of RCTs across orthopedic, dermatologic, and dental applications	Non-peptide. Autologous preparation — no synthetic manufacturing. Largest clinical evidence base in cluster but high study heterogeneity
ARA-290	Synthetic 11-amino-acid peptide (cibinetide; EPO-derived tissue-protective peptide)	Innate Repair Receptor (EPOR/CD131 heterodimer) selective agonist	~2–4 hours	Not FDA-approved (Phase 2b completed)	Not WADA-listed	Tier 2 — Clinical Trials	Peripheral nerves, retina, cardiac, immune system	Subcutaneous injection (1–8 mg daily in trials); IV infusion (early trials)	Phase 2b complete (sarcoidosis SFN — DOSARA trial); Phase 2 (diabetic neuropathy, diabetic macular edema)	EPO-derived but does NOT bind classical EPO receptor. No erythropoietic activity. Tissue protection without blood doping risk. Furthest clinical development for neuropathy

Combination Stacks

Palifermin does not exist in the biohacking combination stack context. It is a hospital-administered IV drug given on a fixed clinical schedule to cancer patients undergoing stem cell transplant. There are no community-reported combinations with other Cluster B peptides.

Clinical combination context: Palifermin is given alongside myeloablative conditioning regimens (total body irradiation + high-dose chemotherapy) as part of standard oncology supportive care. Its value is specifically in combination with these cytotoxic therapies — it would have no role without them.

Why Palifermin Matters for Peptidings Readers

This section addresses the obvious question: why cover a hospital oncology drug on a site about peptide research?

The Evidence Reference Point

Palifermin establishes the evidentiary standard against which every other Cluster B compound is measured. When a reader encounters “mouse studies show healing” for BPC-157 or “in vitro NF-κB inhibition” for KPV, palifermin’s existence answers the implicit question: “What would it take to prove this actually works in humans?”

The answer: a Phase III RCT with 200+ patients, blinded evaluation, validated endpoints, and statistically significant results strong enough for FDA review. That is the distance between Tier 4 and Tier 1.

The Manufacturing Reality Check

Palifermin’s 164-amino-acid size makes it impossible to produce by peptide synthesis. It requires recombinant technology — the same infrastructure used to make insulin, monoclonal antibodies, and other biological drugs. This is why it costs $11,000+ per course. This is why no compounding pharmacy sells it. And this is why the smaller peptides in this cluster (BPC-157 at 15 amino acids, KPV at 3 amino acids) are accessible in ways palifermin never will be. Accessibility and evidence quality do not always correlate.

The Narrow-Approval Lesson

Palifermin is proven for one specific complication of one specific treatment in one specific patient population. It is NOT proven to heal wounds, treat IBD, prevent GVHD, or regenerate tissue in any general sense. The preclinical data for these applications exists, but “preclinical data exists” is exactly where most Cluster B compounds sit — and palifermin’s own history shows how far that is from proven benefit.

Claims vs. Evidence

#	Claim	What the Evidence Shows	Verdict
1	Palifermin prevents severe oral mucositis in stem cell transplant patients	Phase III RCT (n=212, NEJM 2004): Grade 3–4 mucositis 63% vs. 98%. Multiple meta-analyses confirm efficacy. FDA-approved for this indication.	Supported
2	Palifermin reduces the worst (Grade 4) mouth sores	Spielberger 2004: Grade 4 mucositis 20% vs. 62%. Threefold reduction.	Supported
3	Palifermin reduces opioid use and need for IV nutrition	Spielberger 2004: Reduced opioid use; parenteral nutrition 31% vs. 55%.	Supported
4	KGF/palifermin reduces GI mucositis	One RCT in AML patients (n=155): Grade 3–4 GI adverse events 21% vs. 44%, p=0.003 (PMID: 25142189). Not FDA-approved for this indication.	Mixed Evidence
5	KGF promotes wound healing	Animal models only: 92% vs. 40% wound closure in mice. Enhanced epithelialization and vascularization. Zero human wound healing trials.	Preclinical Only
6	KGF prevents GVHD	Preclinical evidence in mouse models. Mixed clinical results in meta-analysis of HSCT trials. Not proven effective.	Preclinical Only
7	KGF regenerates the thymus	Preclinical evidence: KGF expands thymic epithelial cells and promotes T-cell development. Returns to baseline within 2 weeks. No clinical application.	Preclinical Only
8	KGF could treat IBD	No published clinical trial. Theoretical rationale only (FGFR2b expression in GI epithelium).	Theoretical
9	Palifermin causes cancer	In vitro and animal evidence of potential tumor stimulation. Clinical trials showed NO increased cancer risk in hematologic malignancy patients. FDA label includes precautionary warning. Not tested in solid tumor patients.	Unsupported
10	Palifermin is available for self-administration or biohacking	Recombinant protein requiring IV administration. $11,000+ per course. Available only by prescription through hospital pharmacies. No compounding pharmacy or peptide vendor supplies.	Unsupported

Frequently Asked Questions

Summary and Key Takeaways

Palifermin is the anomaly in Cluster B. It is the only compound with FDA approval, the only one backed by a Phase III RCT in a major medical journal, and the only one that nobody in the peptide therapy community will ever use. It exists in this cluster as both a success story and a measuring stick.

The clinical evidence is unambiguous for its approved indication. In cancer patients receiving myeloablative stem cell transplant conditioning, palifermin reduced the incidence of the worst oral mucositis from 98% to 63% — a massive effect in a population where severe mouth sores are otherwise nearly universal. It reduced Grade 4 mucositis threefold. It cut parenteral nutrition requirements nearly in half. The trial was double-blind, placebo-controlled, and published in the New England Journal of Medicine. This is not subtle statistical maneuvering. This is a drug that works.

But the approval is narrow, and the narrowness is the lesson. Palifermin is proven for one specific complication of one specific treatment in one specific patient population. It is NOT proven for wound healing, gut repair, IBD, GVHD, or any of the broader tissue repair applications that define Cluster B’s editorial territory. The preclinical data for these applications exists — KGF promotes epithelial growth in animal wound models, GI models, and thymic models. But palifermin’s own history demonstrates how far preclinical promise sits from clinical proof.

For Peptidings readers, palifermin answers a question that hovers over every other article in this cluster: what does Tier 1 evidence actually look like? It looks like 212 patients, double-blinded, with validated endpoints, published in the NEJM, reviewed by the FDA, and approved for a specific population. That is the standard. The distance between that standard and “reduced colitis in mice” or “promoted wound closure in rats” is the distance this cluster is honest about.

Verdict Recapitulation

Palifermin (Kepivance) received FDA approval on December 15, 2004, based on a Phase III RCT demonstrating significant reduction in severe oral mucositis in hematopoietic stem cell transplant patients (PMID: 15602019). This is the highest evidence tier in the Peptidings system. Critical scope limitation: Tier 1 applies ONLY to the approved indication. For wound healing, GI mucositis, GVHD, thymic regeneration, and all other potential applications, evidence ranges from a single exploratory trial to preclinical only.

Where to Source KGF / Palifermin

Further Reading and Resources

If you want to go deeper on palifermin, the evidence landscape for tissue repair compounds, or the methodology behind how we evaluate this research, these are the places worth your time.

On Peptidings

• BPC-157 — The most-discussed tissue repair peptide in the biohacking community
• GHK-Cu — Copper peptide with wound healing and skin remodeling properties
• Thymosin Beta-4 — Cell migration and tissue repair peptide
• Cluster B: Injury Recovery & Tissue Repair — All compounds in this research category
• Peptidings Evidence Framework — How we assign evidence tiers and verdicts

External Resources

• PubMed — Biomedical Research Database — Search for “palifermin” or “keratinocyte growth factor”
• ClinicalTrials.gov — Check for registered or ongoing trials
• Kepivance FDA Prescribing Information — Official FDA label

Selected References and Key Studies

• Spielberger R, Stiff P, Bensinger W, et al, "Palifermin for oral mucositis after intensive therapy for hematologic cancers." N Engl J Med, 2004;351(25):2590-2598. PubMed
• Finch PW, Rubin JS, "Keratinocyte growth factor/fibroblast growth factor 7, a homeostatic factor with therapeutic potential for epithelial protection and repair." Cytokine Growth Factor Rev, 2004;15(4):115-124. PubMed
• Lucchese A, et al, "Randomized trial of prophylactic palifermin on gastrointestinal toxicity after intensive induction therapy for acute myeloid leukemia." PLoS One, 2014;9(4):e94857. PubMed
• Spielberger R, et al, "Meta-analysis of palifermin efficacy for reducing severe oral mucositis." Crit Rev Oncol Hematol, 2022;170:103579. PubMed
• Nguyen DT, et al, "Efficacy of palifermin on oral mucositis and acute GVHD after hematopoietic stem cell transplantation: meta-analysis." Biomed Res Ther, 2018;5(1):1950-1962. PubMed
• Blijlevens N, et al, "Comparative efficacy and safety of interventions for preventing oral mucositis: network meta-analysis." Support Care Cancer, 2020;28:2943-2955.
• Ornitz DM, Itoh N, "The fibroblast growth factor signaling pathway." WIREs Dev Biol, 2015;4(3):215-266.
• Xie Y, et al, "FGF/FGFR signaling in health and disease." Signal Transduct Target Ther, 2020;5:181.
• Keratinocyte growth factor expression and activity in cancer: implications for use in patients with solid tumors, "KGF in cancer." J Natl Cancer Inst, 2006;98(12):812-824. PubMed
• Rossi S, et al, "KGF enhances postnatal T-cell development via enhancements in proliferation and function of thymic epithelial cells." Blood, 2007;109(9):3803-3811.
• Kepivance (palifermin) prescribing information. FDA. Revised 2019. NDA #125103.
• Drug approval package: Kepivance. FDA Center for Drug Evaluation and Research. 2004.